60 Degrees Pharmaceuticals filings document a specialty pharmaceutical issuer with Nasdaq-listed common stock and warrants, emerging-growth-company status and a business focused on medicines for vector-borne disease. Its recent Form 8-K disclosures record material events involving the company’s at-the-market equity offering program, related legal opinions, beneficial-ownership corrections, investor-presentation materials, and clinical development and regulatory strategy updates.
The filing record also covers capital-structure and governance matters, including a one-for-four reverse stock split approved through amendments to the certificate of incorporation, annual meeting voting results and Nasdaq listing-compliance notices. These disclosures frame the company’s formal reporting around ARAKODA, tafenoquine development, equity financing mechanics, security-holder votes and exchange-related requirements.
60 Degrees Pharmaceuticals, Inc. director Francois Eric filed an initial Form 3, which is a statement of beneficial ownership for insiders. This filing does not list any stock purchases, sales, option exercises, or other transactions, and serves mainly to register his status as a reporting person.
60 Degrees Pharmaceuticals, Inc. reported that its Board of Directors appointed Eric Francois as a director, effective May 13, 2026. He is a veteran healthcare and life sciences financial executive with over 20 years of experience in investment banking, corporate finance, and board roles.
Francois has held senior positions at Raymond James and Credit Suisse, leading equity, debt, and M&A transactions for biotechnology companies. He also previously served as Chief Financial Officer of SCYNEXIS, Inc., where he raised over $300 million in capital and supported the company through FDA approval and commercial launch. He has prior public company board and committee experience and will receive standard non-employee director compensation, with no special arrangements, family relationships, or related-party transactions disclosed.
Knight Therapeutics Inc. filed Amendment No. 3 to its Schedule 13G/A as an exit filing for 60 Degrees Pharmaceuticals, Inc. The amendment states that as of March 31, 2026 the reporting person no longer beneficially owns any shares of the issuer's common stock (CUSIP 83006G104).
The filing reports 0 shares beneficially owned and a 0% ownership percentage, and is signed on May 15, 2026 by Samira Sakhia on behalf of Knight Therapeutics Inc.
60 Degrees Pharmaceuticals reports that CVI Investments, Inc. and Heights Capital Management, Inc. collectively beneficially own 197,911 shares, equal to 7.0% of its common stock. The filing states those shares "consist of Shares issuable upon the exercise of warrants to purchase Shares."
The company had 2,636,788 Shares outstanding as of March 30, 2026. Heights Capital Management is identified as the investment manager to CVI Investments and may exercise voting and dispositive power over the reported shares.
60 Degrees Pharmaceuticals, Inc. reported a net loss attributable to common stockholders of $2.21 million for the quarter ended March 31, 2026, compared with $2.00 million a year earlier. Net product revenue was $162,092, essentially flat versus $163,552 in 2025, while prior-year research revenue of $92,731 did not recur.
Operating expenses rose slightly to $2.17 million, driven mainly by general and administrative costs of $1.89 million, with research and development at $281,464. Cash used in operating activities was $2.74 million, but the company boosted liquidity through at-the-market equity sales, ending the quarter with cash and cash equivalents of $3.34 million.
Management discloses an accumulated deficit of $49.98 million and explicitly states that recurring losses, limited cash runway and funding needs raise substantial doubt about the company’s ability to continue as a going concern for one year from the issuance of these financial statements.
60 Degrees Pharmaceuticals reports beneficial ownership disclosure showing 263,158 shares of Common Stock (approximately 9.1%) attributable collectively to Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC as of the close of business on March 31, 2026.
The filing states the 263,158 shares reflect 131,579 shares issuable upon exercise of each of two warrants held by Intracoastal and is calculated using 2,636,788 shares outstanding as of March 30, 2026. The filing also explains multiple additional warrants contain blocker provisions that limit exercise to avoid exceeding 4.99% ownership; without those blockers, beneficial ownership would be 307,543 shares.
60 Degrees Pharmaceuticals, Inc. files its annual report describing a specialty infectious disease business built around tafenoquine and celgosivir. The company markets Arakoda for malaria prevention and is developing tafenoquine for tick‑borne babesiosis, veterinary babesiosis and respiratory fungal and viral infections.
It strengthened its balance sheet through multiple 2024–2026 equity raises, including at‑the‑market programs and several registered direct and private warrant offerings that collectively brought in several million dollars of net proceeds. The report also details an extensive patent and trademark portfolio and ongoing clinical trials intended to support potential label expansions and new products.
60 Degrees Pharmaceuticals, Inc. filed a Form 8-K to correct an error in previously disclosed share ownership for a company affiliate. A March 13, 2026 prospectus supplement had shown the affiliate as beneficially owning 21,490 shares; the correct figure is 23,367 shares. The error traces back to an incorrect total in a Form 4 dated September 15, 2025 that was carried into a December 16, 2025 Form 4 and then into the prospectus disclosure. After giving effect to the 1-for-4 reverse stock split, the corrected total number of shares beneficially owned is 16,781 instead of 15,905. The company states that no other information in the prospectus supplement is affected.
60 Degrees Pharmaceuticals amended its ATM prospectus to increase the offering capacity to $565,000. This figure gives effect to 325,200 shares previously sold for aggregate gross proceeds of $980,510.52 under the Sales Agreement with H.C. Wainwright & Co.
The supplement states shares outstanding were 2,472,949 and public float was $12,747,587 based on 2,451,459 shares held by non-affiliates and a closing price of $5.20 per share on January 28, 2026. The company effected a one-for-four reverse stock split on January 20, 2026. The last reported sale price on Nasdaq was $2.91 on March 12, 2026.
60 Degrees Pharmaceuticals, Inc. filed a Form 8-K to report that it obtained and filed an updated legal opinion from Sichenzia Ross Ference Carmel LLP covering shares of common stock issued and sold under its at-the-market equity offering program with HC Wainwright & Co., LLC.
The opinion, filed as Exhibit 5.1 with an associated consent in Exhibit 23.1, confirms the validity of shares that may be sold under the program and addresses related legal matters. The company states that this updated opinion does not change the existing terms of the at-the-market program.